Cargando…

A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours

BACKGROUND: The objectives of this phase I study were to assess the safety and tolerability of E7080 in patients with advanced, refractory solid tumours; to determine the maximum tolerated dose (MTD) and pharmacokinetics profile of E7080; and to explore preliminary evidence of its anti-tumour effica...

Descripción completa

Detalles Bibliográficos
Autores principales:	Boss, D S, Glen, H, Beijnen, J H, Keesen, M, Morrison, R, Tait, B, Copalu, W, Mazur, A, Wanders, J, O'Brien, J P, Schellens, J H M, Evans, T R J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2012
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3349182/ https://www.ncbi.nlm.nih.gov/pubmed/22516948 http://dx.doi.org/10.1038/bjc.2012.154

Ejemplares similares

A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080
por: Keizer, Ron J., et al.
Publicado: (2010)

E7080, a multi-targeted tyrosine kinase inhibitor suppresses tumor cell migration and invasion
por: Glen, Hilary, et al.
Publicado: (2011)

A dose-escalation study of indisulam in combination with capecitabine (Xeloda) in patients with solid tumours
por: Siegel-Lakhai, W S, et al.
Publicado: (2008)

Two-stage model-based clinical trial design to optimize phase I development of novel anticancer agents
por: Zandvliet, Anthe S., et al.
Publicado: (2009)

Phase I and pharmacological study of the farnesyltransferase inhibitor tipifarnib (Zarnestra®, R115777) in combination with gemcitabine and cisplatin in patients with advanced solid tumours
por: Siegel-Lakhai, W S, et al.
Publicado: (2005)

Phase 1b study of lenvatinib (E7080) in combination with temozolomide for treatment of advanced melanoma
por: Hong, David S., et al.
Publicado: (2015)

Evaluation of α(2)-Integrin Expression as a Biomarker for Tumor Growth Inhibition for the Investigational Integrin Inhibitor E7820 in Preclinical and Clinical Studies
por: Keizer, Ron J., et al.
Publicado: (2011)

Effects of Ketoconazole on the Pharmacokinetics of Lenvatinib (E7080) in Healthy Participants
por: Shumaker, Robert, et al.
Publicado: (2015)

E7080 (Lenvatinib), a Multi-Targeted Tyrosine Kinase Inhibitor, Demonstrates Antitumor Activities Against Colorectal Cancer Xenografts
por: Wiegering, Armin, et al.
Publicado: (2014)

Antitumor Activity of Lenvatinib (E7080): An Angiogenesis Inhibitor That Targets Multiple Receptor Tyrosine Kinases in Preclinical Human Thyroid Cancer Models
por: Tohyama, Osamu, et al.
Publicado: (2014)

Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours
por: Lankheet, N A G, et al.
Publicado: (2014)

LINC02688 and PP7080 as novel biomarkers in early diagnosis of gastric cancer
por: Fattahi, Sadegh, et al.
Publicado: (2021)

The Role of Natural Products and Their Multitargeted Approach to Treat Solid Cancer
por: Muhammad, Naoshad, et al.
Publicado: (2022)

Mutations in pmrB Confer Cross-Resistance between the LptD Inhibitor POL7080 and Colistin in Pseudomonas aeruginosa
por: Romano, Keith P., et al.
Publicado: (2019)

Clinical response to sunitinib as a multitargeted tyrosine-kinase inhibitor (TKI) in solid cancers: a review of clinical trials
por: Kim, Sungkyoung, et al.
Publicado: (2014)

Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumours.
por: Schellens, J. H., et al.
Publicado: (1996)

Gray Hair Associated with the Multitargeted Receptor Tyrosine Kinase Inhibitor Pazopanib
por: Yun, Hwan-Jung, et al.
Publicado: (2015)

A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine‐refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment
por: Cabanillas, Maria E., et al.
Publicado: (2015)

Phase I study on docetaxel and ifosfamide in patients with advanced solid tumours.
por: Pronk, L. C., et al.
Publicado: (1998)

Effects of 4 multitargeted receptor tyrosine kinase inhibitors on regional hemodynamics in conscious, freely moving rats
por: Carter, Joanne J., et al.
Publicado: (2017)

A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC)
por: Molina, Ana M., et al.
Publicado: (2013)

Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies
por: Deenen, Maarten J., et al.
Publicado: (2011)

Synergistic Effects of Lenvatinib (E7080) and MEK Inhibitors against Anaplastic Thyroid Cancer in Preclinical Models
por: Enomoto, Keisuke, et al.
Publicado: (2021)

Phase I and pharmacological study of the broad-spectrum tyrosine kinase inhibitor JNJ-26483327 in patients with advanced solid tumours
por: Konings, I R H M, et al.
Publicado: (2010)

Importance of highly selective LC–MS/MS analysis for the accurate quantification of tamoxifen and its metabolites: focus on endoxifen and 4-hydroxytamoxifen
por: Jager, N. G. L., et al.
Publicado: (2012)

Long noncoding RNA PP7080 promotes hepatocellular carcinoma development by sponging mir-601 and targeting SIRT1
por: Song, Weifang, et al.
Publicado: (2021)

Pharmacokinetic profile and clinical efficacy of a once-daily ondansetron suppository in cyclophosphamide-induced emesis: a double blind comparative study with ondansetron tablets.
por: de Wit, R., et al.
Publicado: (1996)

Targeting Angiogenesis with Multitargeted Tyrosine Kinase Inhibitors in the Treatment of Non-Small Cell Lung Cancer
por: Scagliotti, Giorgio, et al.
Publicado: (2010)

Differential Inhibitory Actions of Multitargeted Tyrosine Kinase Inhibitors on Different Ionic Current Types in Cardiomyocytes
por: Chang, Wei-Ting, et al.
Publicado: (2020)

Two-stage model-based design of cancer phase I dose escalation trials: evaluation using the phase I program of barasertib (AZD1152)
por: Keizer, Ron J., et al.
Publicado: (2011)

Selecting Multitarget Peptides for Alzheimer’s Disease
por: Kasus-Jacobi, Anne, et al.
Publicado: (2022)

Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization
por: Verheijen, R. B., et al.
Publicado: (2017)

PXR-mediated induction of P-glycoprotein by anticancer drugs in a human colon adenocarcinoma-derived cell line
por: Harmsen, Stefan, et al.
Publicado: (2009)

Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients
por: Tellingen, O van, et al.
Publicado: (1999)

Long-term safety and anti-tumour activity of olaparib monotherapy after combination with carboplatin and paclitaxel in patients with advanced breast, ovarian or fallopian tube cancer
por: van der Noll, Ruud, et al.
Publicado: (2015)

Phase I and pharmacological trial of lapatinib in combination with gemcitabine in patients with advanced breast cancer
por: van der Noll, R., et al.
Publicado: (2015)

Systematic Review and Meta-Analysis of Multitargeted Tyrosine Kinase Inhibitors in Patients With Intractable Metastatic Colorectal Cancer
por: Gao, Zhenzhen, et al.
Publicado: (2020)

MBP-11901 Inhibits Tumor Growth of Hepatocellular Carcinoma through Multitargeted Inhibition of Receptor Tyrosine Kinases
por: Park, Hyun Jin, et al.
Publicado: (2022)

Use of multitarget tyrosine kinase inhibitors to attenuate platelet-derived growth factor signalling in lung disease
por: Kanaan, Rana, et al.
Publicado: (2017)

Human mass balance study of the novel anticancer agent ixabepilone using accelerator mass spectrometry
por: Beumer, J. H., et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_gufgnistebdmo47b0bbothl31r